Prenatal mTOR-Inhibitor Therapy for Fetal Cardiac Rhabdomyomas: Indications, Treatment Duration and Perinatal Outcomes.

Kyvernitakis I, Schramm K, Wiegand G, Feyerabend B, Baschat AA

Open source

DOI
10.3390/jcm15166453
Published
2026 Aug 20
Container
Journal of clinical medicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/jcm15166453,
  title = {Prenatal mTOR-Inhibitor Therapy for Fetal Cardiac Rhabdomyomas: Indications, Treatment Duration and Perinatal Outcomes.},
  author = {Kyvernitakis I and Schramm K and Wiegand G and Feyerabend B and Baschat AA},
  year = {2026},
  journal = {Journal of clinical medicine},
  doi = {10.3390/jcm15166453},
  url = {https://doi.org/10.3390/jcm15166453}
}

RIS

TY  - JOUR
TI  - Prenatal mTOR-Inhibitor Therapy for Fetal Cardiac Rhabdomyomas: Indications, Treatment Duration and Perinatal Outcomes.
AU  - Kyvernitakis I
AU  - Schramm K
AU  - Wiegand G
AU  - Feyerabend B
AU  - Baschat AA
PY  - 2026
JO  - Journal of clinical medicine
DO  - 10.3390/jcm15166453
UR  - https://doi.org/10.3390/jcm15166453
ER  - 

APA

I, K., K, S., G, W., B, F., & AA, B. (2026). Prenatal mTOR-Inhibitor Therapy for Fetal Cardiac Rhabdomyomas: Indications, Treatment Duration and Perinatal Outcomes.. Journal of clinical medicine. https://doi.org/10.3390/jcm15166453

Source records